RxDoctor Payments Data

James Hill, MD

Internal Medicine · Cincinnati, OHNPI 1629034061

Payments from drug & device makers

$299in general payments, 2019–2025

Across 18 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$107
  • Astellas Pharma US Inc$72
  • Metuchen Pharmaceuticals$29
  • Kowa Pharmaceuticals America, Inc.$29
  • Abbott$24
  • GSK$16
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$299100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie5$107
Astellas Pharma US Inc5$72
Metuchen Pharmaceuticals2$29
Kowa Pharmaceuticals America, Inc.2$29
Abbott1$24
GSK1$16
Merck1$11
Novo Nordisk1$11

How this compares

$299 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$169,443
Medicare patients
327
Services billed
3,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$92,599
JardianceEmpagliflozin81$80,662
EliquisApixaban101$69,103
TrulicityDulaglutide29$46,170
XareltoRivaroxaban20$30,994
Breo ElliptaFluticasone/Vilanterol46$23,952
FarxigaDapagliflozin Propanediol15$22,687
ProliaDenosumab12$20,791
OzempicSemaglutide16$20,529
JanumetSitagliptin Phos/Metformin Hcl11$17,416
Janumet XrSitagliptin Phos/Metformin Hcl18$16,551
Tresiba Flextouch U-200Insulin Degludec17$9,998
MyrbetriqMirabegron21$8,894
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,398
BelsomraSuvorexant17$7,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Janumet Xr, Belsomra$11$41,41346 claims
GSKBreo Ellipta, Anoro Ellipta$16$32,35064 claims
Novo NordiskOzempic$11$20,52916 claims
Astellas Pharma US IncMyrbetriq$72$8,89421 claims
AbbVieSynthroid$107$4,10652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →